Emergency Use Authorization by FDA – Baylor Cardiologists Support Hydroxychloroquine
The number of doctors publicly supporting the use of hydroxychloroquine for early treatment or prevention is growing.
Recently, Dr. Kevin R. Wheelan, chief of cardiology at Baylor Heart and Vascular Hospital in Dallas and Dr. Peter McCullough, a clinical cardiologist and professor at the Texas A&M School of Medicine, issued a letter supporting the emergency use authorization (EUA) of hydroxychloroquine for outpatient treatment and prophylaxis for COVID-19.
The letter dated July 6 was submitted in support of a petition by several other doctors asking the Federal Drug Administration (FDA) to reissue an emergency use authorization for hydroxychloroquine that has been donated to the national stockpile.
Wheelan and McCullough say in their letter that “when started earlier in the hospital course…and in outpatients, antimalarials [hydroxychloroquine] may reduce the progression of disease, prevent hospitalizations, and are associated with reduced mortality.” They cite several studies for support.
